Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.61 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7652173 | 0.87 | PPARG (0.56) | PPARGPTPN1IRAK4PDE2APTGER4 | |
| SCHEMBL7660302 | 0.82 | PPARG (0.50) | PPARGPTPN1PTGER4NR1H4 | |
| SCHEMBL7651510 | 0.82 | PPARG (0.69) | PPARGPTPN1ALDH1A1 | |
| SCHEMBL1160303 | 0.81 | PPARG (0.82) | PPARGPTPN1IRAK4PTGER4NPC1 | |
| SCHEMBL1160346 | 0.81 | PPARG (0.81) | PPARGPTPN1IRAK4PTGER4NPC1 | |
| SCHEMBL1160144 | 0.81 | PPARG (0.81) | PPARGPTPN1IRAK4PTGER4NPC1 | |
| SCHEMBL1160232 | 0.79 | PPARG (0.78) | PPARGIRAK4PTGER4NPC1ALDH1A1 | |
| SCHEMBL7657036 | 0.78 | PPARG (0.46) | PPARGIRAK4PDE2APDE10ATP53 | |
| SCHEMBL7650777 | 0.78 | PPARG (0.91) | PPARGIRAK4MAPT | |
| SCHEMBL1179934 | 0.77 | PPARG (0.51) | PPARGPTPN1PDE2APTGER4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6420409-B1 | GLUCOSE TOLERANCE, DIABETES,INSULIN RESISTANCE, POLYCYSTIC OVARY SYNDROME, HYPERLIPIDEMIA, ATHEROSCLEROSIS, CARDIOVASCULAR DISORDERS, HYPERGLYCEMIA, HYPERTENSION, STENOCARDIA, PULMONARY HYPERTENSION, CONGESTIVE HEART FAILURE, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-16 | — | — | US | disclosed |